Abstract:BACKGROUND: Clinical guidelines have traditionally advised annual Chlamydia trachomatis screening for women younger than 25 years of age.OBJECTIVE: To assess the cost-effectiveness of recently proposed strategies for chlamydia screening.DESIGN: State transition simulation model; cost-effectiveness analysis.DATA SOURCES: Published literature.TARGET POPULATION: Sexually active U.S. women 15 to 29 years of age.TIME HORIZON: Lifetime.PERSPECTIVE: Modified societal.INTERVENTIONS: Four strategies targeted to 3 specific age groups (15 to 19 years, 15 to 24 years, and 15 to 29 years): 1) no screening, 2) annual screening for all women, 3) annual screening followed by 1 repeated test within 3 to 6 months after a positive test result, and 4) annual screening followed by selective semiannual screening for women with a history of infection.OUTCOME MEASURES: Clinical events (for example, pelvic inflammatory disease, chronic pelvic pain, ectopic pregnancy, and infertility), lifetime costs, quality-adjusted life expectancy, and incremental cost-effectiveness ratios.RESULTS OF BASE-CASE ANALYSIS: Annual screening in women 15 to 29 years of age followed by semiannual screening for those with a history of infection was the most effective and cost-effective strategy. It consistently had an incremental cost-effectiveness ratio less than 25,000 dollars per quality-adjusted life-year (QALY) compared with the next most effective strategy. When the indirect transmission effects of a 10-year screening program on the probability of infection in uninfected women (that is, per-susceptible rate of infection) were considered, all strategies became more cost-effective.RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to the annual incidence of chlamydia, probability of persistent infection, screening test costs, and costs of treating long-term complications. Each variable was associated with threshold values beyond which screening became cost-saving. In probabilistic analysis, annual screening in women 15 to 29 years of age followed by semiannual screening for those with a history of infection had an incremental cost-effectiveness ratio less than 50,000 dollars per QALY in 99% of simulations.LIMITATIONS: Uncertainty about the natural history of chlamydial infection and consideration of only the indirect transmission effects of C. trachomatis screening.CONCLUSIONS: Annual C. trachomatis screening for all women 15 to 29 years of age and selective targeting of those with a history of infection for semiannual screening is very cost-effective compared with other well-accepted clinical interventions.

Spontaneous Clearance of Chlamydia trachomatis and Its Associated Factors among Women Attending Screening for Chlamydia in Shenzhen, China.

Prevalence of and risk factors for chlamydia in female outpatients with genital tract infections: a nationwide multi-center, cross-sectional study in China

The screening of Chlamydia Trachomatis on the normal women in Beijing and its clinical significance

Incidence and spontaneous clearance of gonorrhea and chlamydia infections among men who have sex with men: a prospective cohort study in Zhuhai, China

Distribution of Chlamydia trachomatis ompA genotypes and its association with abnormal cervical cytology among women of reproductive age in Shenzhen, China

Prevalence of Chlamydia trachomatis Infection in Young Women and Associated Predictors

Reproductive tract complication risks following Chlamydia trachomatis infections: a long-term prospective cohort study from 2008 to 2022

Screening for Chlamydia trachomatis in Women 15 to 29 Years of Age: A Cost-Effectiveness Analysis

Chlamydia Trachomatis Prevalence in Asymptomatic Women in Madrid: Study Findings and Their Association with Risk Factors and Mental Health

Unintended pregnancy and its correlates among female attendees of sexually transmitted disease clinics in Eastern China.

Characterization of genital chlamydia trachomatis infection among women attending infertility and gynecology clinics in Hunan, China

Persistent Genital Chlamydia Trachomatis Infection among Women

Uptake and correlates of chlamydia and gonorrhea testing among female sex workers in Southern China: a cross-sectional study

Presence of Chlamydia Trachomatis and Mycoplasma Spp., but Not Neisseria Gonorrhoeae and Treponema Pallidum, in Women Undergoing an Infertility Evaluation: High Prevalence of Tetracycline Resistance Gene Tet(m)

High Prevalence of Rectal Chlamydia trachomatis Infection With the Same Genotype as Urogenital Infection in Female Outpatients in Sexually Transmitted Disease Clinics in China

Prevalence of Mycoplasma genitalium and Chlamydia trachomatis in Chinese female with lower reproductive tract infection: a multicenter epidemiological survey

Prevalence of Ureaplasma Urealyticum, Chlamydia Trachomatis, and Neisseria Gonorrhoeae in Gynecological Outpatients, Taizhou, China

Detection of Chlamydia trachomatis in rectal specimens in women and its association with anal intercourse: a systematic review and meta-analysis

Modelling the Impact of Screening Men for Chlamydia Trachomatis on the Prevalence in Women

Comparative Study in Infertile Couples with and Without Chlamydia Trachomatis Genital Infection

Determinants and prediction of Chlamydia trachomatis re-testing and re-infection within 1 year among heterosexuals with chlamydia attending a sexual health clinic